Skip to main content

Table 1 Patient and clinical characteristics for all the 87 patients considered for analysis

From: Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography

Patient and clinical characteristics Number of patients Age (mean ± SD) BMI (mean ± SD)
Chemotherapy and targeted therapies
 T × 12/AC × 4 54 48.48 ± 11.52 29.89 ± 7.18
 TCHP × 6 21 53.80 ± 10.04 29.307 ± 9.49
 TC ×  6 6 59.67 ± 12.24 30.54 ± 3.24
 T/C × 12/AC × 4 4 39.25 ± 8.65 30.05 ± 2.29
 TC × 4 1 30 18.11
 THP × 12/AC × 4 1 40 32.23
Menopausal status
 Premenopausal 52 41.65 ± 6.90 29.48 ± 7.91
 Postmenopausal 34 61.63 ± 6.00 30.10 ± 6.82
 Uncertain 1 56 27.16
Tumor characteristics Number of tumors
Treatment response classification
 pCR
 RCB 0 36
 Non-pCR
 RCB I 10
 RCB II 27
 RCB III 11
 RCB score not available 3
  1. Abbreviations and acronyms: T × 12/AC × 4, 12 cycles of weekly paclitaxel followed by 4 cycles of doxorubicin and cyclophosphamide given every 2 weeks with growth factor support; T/C × 12/AC × 4, 12 cycles of weekly paclitaxel followed by 4 cycles of doxorubicin and cyclophosphamide given every 2 weeks with growth-factor support with an addition of carboplatin to paclitaxel; TC × 6, six cycles Cytoxan plus Taxotere; TC × 4, four cycles Cytoxan plus Taxotere; TCHP, six cycles of docetaxel, carboplatin, and trastuzumab plus pertuzumab; THP/AC, paclitaxel, trastuzumab, and pertuzumab followed by doxorubicin and cyclophosphamide; pCR, pathologic complete response; RCB, residual cancer burden; BMI, body mass index; SD, standard deviation